Bavarian Nordic (BAVA) - Total Liabilities
Based on the latest financial reports, Bavarian Nordic (BAVA) has total liabilities worth Dkr2.08 Billion DKK (≈ $326.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Bavarian Nordic's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Bavarian Nordic - Total Liabilities Trend (2000–2025)
This chart illustrates how Bavarian Nordic's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BAVA total asset value.
Bavarian Nordic Competitors by Total Liabilities
The table below lists competitors of Bavarian Nordic ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asker Healthcare
ST:ASKER
|
Sweden | Skr10.81 Billion |
|
Tenable Holdings Inc
NASDAQ:TENB
|
USA | $1.37 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $222.86 Million |
|
Voltronic Power Technology Corp
TW:6409
|
Taiwan | NT$7.46 Billion |
|
Newell Brands Inc
NASDAQ:NWL
|
USA | $8.61 Billion |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
China | CN¥7.41 Billion |
|
Central Puerto S.A.
BA:CEPU
|
Argentina | AR$1.25 Trillion |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
USA | $396.88 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Bavarian Nordic's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Bavarian Nordic (BAVA) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bavarian Nordic's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bavarian Nordic (2000–2025)
The table below shows the annual total liabilities of Bavarian Nordic from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr2.08 Billion ≈ $326.13 Million |
-30.46% |
| 2024-12-31 | Dkr3.00 Billion ≈ $468.95 Million |
-25.32% |
| 2023-12-31 | Dkr4.01 Billion ≈ $627.91 Million |
-23.43% |
| 2022-12-31 | Dkr5.24 Billion ≈ $820.03 Million |
+11.17% |
| 2021-12-31 | Dkr4.71 Billion ≈ $737.63 Million |
+21.99% |
| 2020-12-31 | Dkr3.86 Billion ≈ $604.66 Million |
-25.41% |
| 2019-12-31 | Dkr5.18 Billion ≈ $810.70 Million |
+488.61% |
| 2018-12-31 | Dkr880.31 Million ≈ $137.73 Million |
+36.19% |
| 2017-12-31 | Dkr646.37 Million ≈ $101.13 Million |
-19.85% |
| 2016-12-31 | Dkr806.46 Million ≈ $126.18 Million |
+24.69% |
| 2015-12-31 | Dkr646.78 Million ≈ $101.19 Million |
+1.83% |
| 2014-12-31 | Dkr635.17 Million ≈ $99.38 Million |
+33.46% |
| 2013-12-31 | Dkr475.92 Million ≈ $74.46 Million |
-11.79% |
| 2012-12-31 | Dkr539.50 Million ≈ $84.41 Million |
-29.84% |
| 2011-12-31 | Dkr768.99 Million ≈ $120.31 Million |
+17.10% |
| 2010-12-31 | Dkr656.69 Million ≈ $102.74 Million |
+15.84% |
| 2009-12-31 | Dkr566.89 Million ≈ $88.69 Million |
-16.53% |
| 2008-12-31 | Dkr679.13 Million ≈ $106.26 Million |
+32.03% |
| 2007-12-31 | Dkr514.39 Million ≈ $80.48 Million |
+95.57% |
| 2006-12-31 | Dkr263.02 Million ≈ $41.15 Million |
-11.87% |
| 2005-12-31 | Dkr298.46 Million ≈ $46.70 Million |
+4.10% |
| 2004-12-31 | Dkr286.71 Million ≈ $44.86 Million |
+248.93% |
| 2003-12-31 | Dkr82.17 Million ≈ $12.86 Million |
-32.24% |
| 2002-12-31 | Dkr121.26 Million ≈ $18.97 Million |
+583.90% |
| 2001-12-31 | Dkr17.73 Million ≈ $2.77 Million |
-17.02% |
| 2000-12-31 | Dkr21.37 Million ≈ $3.34 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more